Pyxis Oncology Q2 EPS $(0.29) Misses $(0.28) Estimate
Portfolio Pulse from Benzinga Newsdesk
Pyxis Oncology (NASDAQ:PYXS) reported a Q2 EPS of $(0.29), missing the analyst consensus estimate of $(0.28) by 3.57%. However, this represents a 29.27% improvement over the $(0.41) loss per share from the same period last year.
August 14, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pyxis Oncology reported a Q2 EPS of $(0.29), missing the consensus estimate of $(0.28) by 3.57%. Despite the miss, the EPS improved by 29.27% compared to the same period last year.
The EPS miss, although slight, is likely to have a negative short-term impact on the stock price. However, the significant year-over-year improvement may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100